Ballentine Partners LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,074 shares of the company’s stock, valued at approximately $259,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of LLY. First Command Financial Services Inc. raised its position in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock worth $103,000 after buying an additional 84 shares during the last quarter. Heritage Trust Co bought a new position in shares of Eli Lilly and during the first quarter worth about $135,000. Point72 Asia Hong Kong Ltd raised its position in shares of Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares during the last quarter. Penserra Capital Management LLC raised its position in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares during the last quarter. Finally, Crestwood Advisors Group LLC bought a new position in shares of Eli Lilly and during the first quarter worth about $179,000. Institutional investors and hedge funds own 75.59% of the company’s stock.

Eli Lilly and Company (NYSE LLY) traded up 0.13% during trading on Wednesday, reaching $81.82. 551,806 shares of the company’s stock traded hands. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72. The firm’s 50 day moving average price is $82.77 and its 200-day moving average price is $81.92. The stock has a market cap of $86.32 billion, a P/E ratio of 35.40 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. Eli Lilly and’s revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.86 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be paid a $0.52 dividend. The ex-dividend date is Friday, August 11th. This represents a $2.08 annualized dividend and a yield of 2.55%. Eli Lilly and’s dividend payout ratio is currently 90.04%.

COPYRIGHT VIOLATION WARNING: “3,074 Shares in Eli Lilly and Company (LLY) Acquired by Ballentine Partners LLC” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.watchlistnews.com/3074-shares-in-eli-lilly-and-company-lly-acquired-by-ballentine-partners-llc/1495203.html.

A number of research analysts have issued reports on the stock. BMO Capital Markets restated a “sell” rating and set a $73.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. Berenberg Bank restated a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. Leerink Swann lowered shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and cut their price target for the company from $93.00 to $90.00 in a research note on Wednesday, July 26th. TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Finally, BidaskClub upgraded shares of Eli Lilly and from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $88.27.

In other Eli Lilly and news, insider Melissa S. Barnes sold 1,900 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the sale, the insider now directly owns 14,041 shares in the company, valued at approximately $1,134,231.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the sale, the vice president now owns 62,056 shares in the company, valued at $4,962,618.32. The disclosure for this sale can be found here. Insiders sold a total of 669,733 shares of company stock worth $55,845,287 over the last three months. 0.20% of the stock is currently owned by corporate insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.